1
Clinical Trials associated with Bcl-Xl_42-CAF09b vaccine(Herlev Hospital)A Phase I Study of the Bcl-XL_42-CAF09b Vaccine to Test Safety and Immunological Effect in Patients With Prostate Cancer With Lymph Node Metastases
In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b. The aim of the study is to clarify the safety and toxicity of the vaccine and also the immunological effect.
The vaccine Bcl-xl_42-CAF09b is composed of the peptide Bcl-xl_42 and the adjuvant CAF09b. The B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases. Bcl-xl_42 is a peptide fragment of the full protein and preclinical studies have shown that vaccination with this peptide (Bcl-xl) can activate the immune system and thereby lead to the death of cancer cells. In order to improve the activation of the immune system, adjuvant CAF09b is added; Preclinical studies have shown that special intraperitoneal (IP) injections of CAF09b improve the activation of the immune system.
100 Clinical Results associated with Bcl-Xl_42-CAF09b vaccine(Herlev Hospital)
100 Translational Medicine associated with Bcl-Xl_42-CAF09b vaccine(Herlev Hospital)
100 Patents (Medical) associated with Bcl-Xl_42-CAF09b vaccine(Herlev Hospital)
100 Deals associated with Bcl-Xl_42-CAF09b vaccine(Herlev Hospital)